Evaluating statewide HIV preexposure prophylaxis implementation using All-Payer Claims Data

Evaluating Healthcare Claims for Neurocysticercosis by Using All-Payer All-Claims Data, Oregon, 2010–2013

To characterize the frequency of neurocysticercosis, associated diagnostic codes, and place of infection, we searched Oregon's All Payer All-Claims dataset for 2010-2013. Twice as many cases were found by searching inpatient and outpatient data than by inpatient data alone. Studies relying exclusively on inpatient data underestimate frequency and miss less severe disease.

Preexposure Prophylaxis for HIV Prevention

This interactive feature addresses the diagnosis or management of a clinical case. A case vignette is followed by specific clinical options, none of which can be considered either correct or incorrect. In short essays, experts in the field then argue for each of the options. In the online version of this feature, available at NEJM.org, readers can participate in forming community opinion by cho...

Streamlining HIV testing for HIV preexposure prophylaxis.

HIV-testing algorithms for preexposure prophylaxis (PrEP) should be optimized to minimize the risk of drug resistance, the time off PrEP required to evaluate false-positive screening results, and costs and to expedite the start of therapy for those confirmed to be infected. HIV rapid tests (RTs) for anti-HIV antibodies provide results in less than 1 h and can be conducted by nonlicensed staff a...

HIV preexposure prophylaxis: new data and potential use.

HIV preexposure prophylaxis (PrEP) has demonstrated efficacy in 4 studies: 1) the CAPRISA 004 trial of pericoital administration of 1% tenofovir gel showed moderate (39%) efficacy in reducing risk of HIV acquisition in young women; 2) the iPrEx trial of daily oral emtricitabine/tenofovir had moderate (44%) efficacy in reducing risk of HIV acquisition among high-risk men who have sex with men (M...

Ethical allocation of preexposure HIV prophylaxis.